+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oxford Immunotec Ltd - Product Pipeline Analysis, 2021 Update

Oxford Immunotec Ltd (Oxford Immunotec) a subsidiary of Oxford Immunotec Global Plc is a medical device company that offers proprietary tests for immune-regulated conditions. The company offers in vitro diagnostic, T-SPOT CMV Test, C6 Lyme ELISA Test, T-Cell Xtend Reagent. It offers T-SPOT.TB test that diagnoses both latent TB infection and active disease by measuring T cells that have been activated by Mycobacterium tuberculosis antigens. Oxford Immunotec’s T-SPOT solution offers diagnosing disease by measuring immune response to an infection. The company offers laboratories services such as oxford diagnostics. It operates in the US, the UK, Japan, South Korea and China. Oxford Immunotec is headquartered in Abingdon, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and helps to create effective counter strategies to gain a competitive advantage.

Scope
  • The report reviews the detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Oxford Immunotec Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides a detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date

Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Oxford Immunotec Ltd Company Overview
  • Oxford Immunotec Ltd Company Snapshot
  • Oxford Immunotec Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Oxford Immunotec Ltd - Pipeline Analysis Overview
  • Oxford Immunotec Ltd - Key Facts
  • Oxford Immunotec Ltd - Major Products and Services
  • Oxford Immunotec Ltd Pipeline Products by Development Stage
  • Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status

Oxford Immunotec Ltd Pipeline Products Overview
  • B Cell ELISPOT Assay
  • B Cell ELISPOT Assay Product Overview
  • Diagnostic Test - Autoimmune and Inflammatory Disease
  • Diagnostic Test - Autoimmune and Inflammatory Disease Product Overview
  • Diagnostic Test - Chronic Infections
  • Diagnostic Test - Chronic Infections Product Overview
  • ELISPOT Tumor Assay
  • ELISPOT Tumor Assay Product Overview
  • I-O Monitoring Test
  • I-O Monitoring Test Product Overview
  • Metabovis Assay - Homocysteine
  • Metabovis Assay - Homocysteine Product Overview
  • Risk Stratification System - Kidney Transplantation
  • Risk Stratification System - Kidney Transplantation Product Overview
  • SpiroFind
  • SpiroFind Product Overview
  • Stratokine
  • Stratokine Product Overview
  • T-Cell Select
  • T-Cell Select Product Overview
  • T-SPOT.COVID Test
  • T-SPOT.COVID Test Product Overview
  • T-SPOT.COVID Test Clinical Trial
  • T-SPOT.ICA
  • T-SPOT.ICA Product Overview
  • UREA and T-SPOT Based Diagnostic Assay - Immunological Disease
  • UREA and T-SPOT Based Diagnostic Assay - Immunological Disease Product Overview
  • UREA and T-SPOT Based Diagnostic Assay - Infectious Disease
  • UREA and T-SPOT Based Diagnostic Assay - Infectious Disease Product Overview

Oxford Immunotec Ltd - Key CompetitorsOxford Immunotec Ltd - Key Employees
Oxford Immunotec Ltd - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • Oxford Immunotec Ltd, Recent Developments
  • Oct 21, 2020: Oxford Immunotec Schedules Third Quarter 2020 Earnings Release and Conference Call for November 3, 2020
  • Aug 04, 2020: Oxford Immunotec reports second quarter 2020 financial results
  • Jul 21, 2020: Oxford Immunotec Schedules Second Quarter 2020 Earnings Release and Conference Call for August 4, 2020
  • Apr 29, 2020: Oxford Immunotec Schedules First Quarter 2020 Earnings Release and Conference Call for May 5, 2020
  • Feb 24, 2020: Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020
  • Feb 20, 2020: Oxford Immunotec announces new data on the utility of T-SPOT.CMV in kidney and stem cell transplant
  • Jan 23, 2020: Oxford Immunotec announces donation in support of Coronavirus testing efforts to help differentiate Tuberculosis from the new China virus
  • Nov 05, 2019: Oxford Immunotec reports third quarter 2019 financial results
  • Aug 06, 2019: Oxford Immunotec reports second quarter 2019 financial results
  • Jun 24, 2019: Oxford Immunotec appoints Patrick J. Balthrop, Sr. as Chairman

Appendix
  • Methodology
  • About the Publisher

List of Tables
  • Oxford Immunotec Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Oxford Immunotec Ltd Pipeline Products by Equipment Type
  • Oxford Immunotec Ltd Pipeline Products by Indication
  • Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
  • Oxford Immunotec Ltd, Key Facts
  • Oxford Immunotec Ltd, Major Products and Services
  • Oxford Immunotec Ltd Number of Pipeline Products by Development Stage
  • Oxford Immunotec Ltd Pipeline Products Summary by Development Stage
  • Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status
  • Oxford Immunotec Ltd Ongoing Clinical Trials Summary
  • B Cell ELISPOT Assay - Product Status
  • B Cell ELISPOT Assay - Product Description
  • Diagnostic Test - Autoimmune and Inflammatory Disease - Product Status
  • Diagnostic Test - Autoimmune and Inflammatory Disease - Product Description
  • Diagnostic Test - Chronic Infections - Product Status
  • Diagnostic Test - Chronic Infections - Product Description
  • ELISPOT Tumor Assay - Product Status
  • ELISPOT Tumor Assay - Product Description
  • I-O Monitoring Test - Product Status
  • I-O Monitoring Test - Product Description
  • Metabovis Assay - Homocysteine - Product Status
  • Metabovis Assay - Homocysteine - Product Description
  • Risk Stratification System - Kidney Transplantation - Product Status
  • Risk Stratification System - Kidney Transplantation - Product Description
  • SpiroFind - Product Status
  • SpiroFind - Product Description
  • Stratokine - Product Status
  • Stratokine - Product Description
  • T-Cell Select - Product Status
  • T-Cell Select - Product Description
  • T-SPOT.COVID Test - Product Status
  • T-SPOT.COVID Test - Product Description
  • T-SPOT.COVID Test - A Phase I/II Randomized, Two Parts, Dose-finding Study to Evaluate the Safety, Tolerability and Immunogenicity of an Inactivated, Adjuvanted Sars-Cov-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 in Healthy Subjects
  • T-SPOT.COVID Test - COVID Infection in Patients with Antibody Deficiency: COV-AD
  • T-SPOT.ICA - Product Status
  • T-SPOT.ICA - Product Description
  • UREA and T-SPOT Based Diagnostic Assay - Immunological Disease - Product Status
  • UREA and T-SPOT Based Diagnostic Assay - Immunological Disease - Product Description
  • UREA and T-SPOT Based Diagnostic Assay - Infectious Disease - Product Status
  • UREA and T-SPOT Based Diagnostic Assay - Infectious Disease - Product Description

Oxford Immunotec Ltd, Key Employees
  • Oxford Immunotec Ltd, Subsidiaries
  • Glossary

List of Figures
  • Oxford Immunotec Ltd Pipeline Products by Equipment Type
  • Oxford Immunotec Ltd Pipeline Products by Development Stage
  • Oxford Immunotec Ltd Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • RUA Life Sciences Plc
  • CME Medical UK Ltd
  • Arcomedical Infusion Ltd